The top-tier “pharmerging” markets – led by China, India, Brazil and Russia – accounted for one-third of the world’s pharmaceutical sales growth in 2009 with a second tier of over a dozen more waiting to be tapped.

Capitalizing on this potential needs to be a strategic priority for multi-national pharmaceutical companies since growth opportunities are dwindling in more developed markets.

Succeeding in diverse and far-reaching areas is not a simple matter of doing what’s worked elsewhere. Each pharmerging market has its own risks, challenges, and nuances. And each calls for a unique approach.

Intasol’s end-to-end solutions – integrating unparalleled information, analytics, consulting and services – play a central role in supporting high quality, cost effective healthcare marketing solutions.